Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Change in Accured Expenses (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Change in Accured Expenses for 11 consecutive years, with -$1.1 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses changed N/A to -$1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $5.4 million for FY2025, 3333.7% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$1.1 million at Crescent Biopharma, down from $5.7 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $5.7 million in Q2 2025, with the low at -$2.9 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is -$249383.9, with a median of -$449503.5 recorded in 2021.
  • Peak annual rise in Change in Accured Expenses hit 149.06% in 2022, while the deepest fall reached 850.29% in 2022.
  • Over 5 years, Change in Accured Expenses stood at $881616.0 in 2021, then surged by 33.89% to $1.2 million in 2022, then plummeted by 107.27% to -$85820.0 in 2023, then tumbled by 1435.44% to -$1.3 million in 2024, then increased by 19.63% to -$1.1 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$1.1 million, $5.7 million, and -$2.9 million for Q4 2025, Q2 2025, and Q1 2025 respectively.